Home 
HOME Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.8, p.598–604,2021
HOME Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.8, p.598–604,2021
Journal info
|
||||
Select Journal
Journals
Bratislava Medical Journal 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Bratislava Medical Journal Vol.122, No.8, p.598–604,2021 |
||
| Title: Evaluation of index of cardiac electrophysiological balance in COVID-19 patients | ||
| Author: R. Asoglu, H. Tibilli, E. Asoglu, N Aladag, M. Ozdemir, A. Suner | ||
| Abstract: AIM: The aim of the current study was to evaluate the index of Cardiac Electrophysiological Balance (iCEB) in hospitalized COVID-19 patients receiving Hydroxychloroquine / azithromycin (HCQ / AZ) combination therapy to determine the susceptibility to ventricular arrhythmia among these patients. METHOD: Sixty-seven COVID-19 patients admitted to the ward were included in the study. Electrocardiograms (ECGs) were obtained from all patients before the initiation of treatment and on treatment day 5. QT/QRS (iCEB) and QTc/QRS (iCEBc) ratios were calculated. RESULTS: QRS, QT and QTc intervals were significantly prolonged on day 5 measurements compared to pre-treatment period (p <0.05). Overall, mean iCEB was 3.6±0.4 before treatment and 3.8±0.4 on day 5 in the study population (p <0.001). Considering the iCEBc values, a significant increase was observed in patients receiving HCQ/AZ treatment compared to pre-treatment period (4.1±0.5 vs 4.4±0.6; p <0.001). CONCLUSIONS: To the best of our knowledge, this was the first study to investigate iCEB and iCEBc parameters in patients with COVID-19 on HCQ/AZ therapy. In this study, we demonstrated significantly increased iCEB and iCEBc values following HCQ/AZ treatment in COVID-19 patients. iCEB and iCEBc may serve as a noninvasive, simple, and novel biomarker for detecting increased pro-arrhythmia risk in COVID-19 patients (Tab. 3, Fig. 3, Ref. 36). |
||
| Keywords: COVID-19, index of Cardiac Electrophysiological Balance (iCEB), Hydroxychloroquine, azithromycin, ventricular arrhythmia | ||
| Published online: 20-Jul-2021 | ||
| Year: 2021, Volume: 122, Issue: 8 | Page From: 598, Page To: 604 | |
| doi:10.4149/BLL_2021_096 |
||
|
|
 download file |
|